Thermo Fisher Scientific Inc. (TMO) Stock Price & Analysis
Thermo Fisher Scientific Inc. (TMO) closed at USD 676.54 on Thursday, October 22, 2026, down 2.52% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 694.02; the Oct 22, 2026 session ranged USD 674.2–703.2 on volume of 3,599,891 shares. Market capitalization is $250.15B, with a 52-week range of USD 435.27–705.79 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:14 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TMO.md
Latest Earnings Results (TMO)
Thermo Fisher Scientific Inc. (TMO) reported Q3 2026 results on Oct 21, 2026, 6:03:16 AM ET: GAAP EPS $4.64, revenue $12.14B vs. estimate $11.95B (beat). Guidance: The company will provide updated 2026 financial guidance during its earnings conference call. Source: SEC 8-K filing. Nexqual published it 118 seconds after release. Read the SEC filing.
| Fiscal period | EPS (reported) | Revenue | Released | Source |
|---|---|---|---|---|
| Q3 2026 | $4.64 (GAAP diluted) | $12.14B | Oct 21, 2026, 6:03:16 AM ET · on Nexqual +118 seconds | SEC 8-K filing |
Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.
Key facts (TMO)
- Last four reported quarters (through Jun 27, 2026): revenue $46.3B, net income $6.97B (15.0% margin), free cash flow $7.32B (SEC filings).
- Valuation: P/E 35.9x (avg 32.9x at the last 3 fiscal year-ends), EV/EBITDA 31.4x, net debt $41.6B.
- 12 of 80 tracked superinvestors hold TMO (13F, Q2 2026 (2 investors on Q3 2026, filed early)): 3 new, 5 added, 3 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 12 Form 4 filings, $61.7M; 3 not under a Rule 10b5-1 plan ($10.7M); 3 by opportunistic insiders (0 outside 10b5-1 plans), 5 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.11 on a 1–5 scale) (27 analysts), mean target USD 750.92 (range 560–830).
- Total return with dividends: 1Y +18.7% vs S&P 500 +14.9%; 5Y +12.1% vs S&P 500 +80.3%.
- Next earnings: 2026-10-21, EPS estimate USD 7.14, revenue estimate $12.9B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TMO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $39.2B | $44.9B | $42.9B | $42.9B | $44.6B | $46.3B |
| Operating income | $10.0B | $8.39B | $6.86B | $7.34B | $7.75B | $8.15B |
| Net income | $7.73B | $6.96B | $6.00B | $6.33B | $6.70B | $6.97B |
| EPS (diluted) | $19.46 | $17.63 | $15.45 | $16.53 | $17.74 | — |
| Free cash flow | $6.79B | $6.91B | $6.93B | $7.27B | $6.29B | $7.32B |
| Operating margin | 25.6% | 18.7% | 16.0% | 17.1% | 17.4% | 17.6% |
| Net margin | 19.7% | 15.5% | 14.0% | 14.8% | 15.0% | 15.0% |
| Revenue growth | +21.7% | +14.5% | -4.6% | +0.1% | +3.9% | — |
| Cash + short-term investments | $4.48B | $8.52B | $8.08B | $5.57B | $10.1B | — |
| Total debt | $37.2B | $39.9B | $38.3B | $33.3B | $42.7B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 27, 2026) (TMO)
P/E 35.9x · P/S 5.4x · EV/EBITDA 31.4x · EV/Sales 6.3x · P/FCF 34.2x · P/B 4.8x · FCF yield 2.93% · Earnings yield 2.79% · Dividend yield (paid, TTM) 0.26% · Buyback yield (TTM) 2.00% · Net debt $41.6B · EV $292B
P/E at fiscal year-ends: Dec 2025 32.7x, Dec 2024 31.5x, Dec 2023 34.4x.
Superinvestors (SEC 13F-HR, Q2 2026) (TMO)
12 of 80 tracked investors hold TMO (2 investors on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Lindsell Train | 9.81% | $258M | Reduced -16.6% | Q2 2026 | |
| Wallace Weitz | Weitz Investment Management | 4.00% | $57.8M | Reduced -4.8% | Q2 2026 |
| Viking Global | Viking Global Investors | 2.77% | $971M | Added +16.1% | Q2 2026 |
| Harry Burn | Sound Shore | 2.55% | $82.9M | New position | Q2 2026 |
| First Pacific Advisors | 1.56% | $124M | Added +11.9% | Q2 2026 | |
| Van Den Berg Management I | 1.51% | $7.2M | Added +1.0% | Q2 2026 | |
| John Armitage | Egerton Capital | 1.36% | $134M | New position | Q3 2026 |
| David Katz | Matrix Asset Advisors | 1.33% | $16.2M | Reduced -13.4% | Q3 2026 |
| Dodge & Cox Funds | Dodge & Cox | 0.80% | $1.53B | New position | Q2 2026 |
| Thomas Gayner | Markel Group | 0.28% | $36.6M | Added +8.9% | Q2 2026 |
| Hillman Capital | Hillman Capital Management | 0.27% | $376K | Added +14.3% | Q2 2026 |
| Mairs & Power | Mairs & Power Funds | 0.01% | $622K | Unchanged | Q2 2026 |
Insider sales (SEC Form 4, open-market, last ~7 months) (TMO)
9 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Pettiti Gianluca | President & COO | 4,133 | $2.5M | 15.1% | Yes (adopted June 2, 2026) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-24 | Casper Marc N | Chairman & CEO | 275 | $172K | 0.2% | Yes (adopted April 27, 2026) | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-08-20…2026-08-21 | Casper Marc N | Chairman & CEO | 20,000 | $12.6M | 12.5% | Yes (adopted April 27, 2026) | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-08-19 | Britt Lisa P. | Sr. VP and Chief HR Officer | 11,440 | $7.0M | 43.6% | No | Too little history (no open-market trades in 2023) |
| 2026-08-11 | Shafer Michael D | Executive Vice President | 25,500 | $15.3M | 54.8% | Yes (adopted December 11, 2025) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-07 | Holmes Joseph R. | VP & Chief Accounting Officer | 420 | $246K | 12.4% | No | Too little history (no open-market trades in 2023) |
| 2026-08-07 | Casper Marc N | Chairman & CEO | 4,883 | $2.9M | 3.4% | Yes (adopted April 27, 2026) | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-08-06 | Britt Lisa P. | Sr. VP and Chief HR Officer | 5,850 | $3.4M | 28.4% | No | Too little history (no open-market trades in 2023) |
| 2026-08-06 | Casper Marc N | Chairman & CEO | 15,000 | $8.6M | 10.5% | Yes (adopted April 27, 2026) | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-08-05 | Casper Marc N | Chairman & CEO | 15,000 | $8.6M | 10.1% | Yes (adopted April 27, 2026) | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-07-27 | Pettiti Gianluca | President & COO | 400 | $226K | 1.6% | Yes (adopted September 12, 2025) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-04-27 | Pettiti Gianluca | President & COO | 400 | $185K | 1.6% | Yes (adopted September 12, 2025) | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (TMO)
Consensus Buy (mean 2.11 on a 1–5 scale), 27 analysts; mean target USD 750.92 (low 560, high 830).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Barclays | Target raised | Overweight | $750 → $775 |
| 2026-10-22 | RBC Capital | Target raised | Sector Perform | $580 → $730 |
| 2026-10-22 | TD Cowen | Target raised | Buy | $760 → $810 |
| 2026-10-22 | Stifel | Target raised | Buy | $650 → $775 |
| 2026-10-22 | Baird | Target raised | Outperform | $723 → $756 |
| 2026-10-13 | Morgan Stanley | Target raised | Overweight | $650 → $730 |
| 2026-10-13 | TD Cowen | Target raised | Buy | $675 → $760 |
| 2026-10-07 | Barclays | Target raised | Overweight | $650 → $750 |
| 2026-09-03 | CLSA | Initiated | Outperform | $748 |
| 2026-07-27 | Piper Sandler | Target raised | Neutral | $510 → $600 |
| 2026-07-27 | Morgan Stanley | Target raised | Overweight | $620 → $650 |
| 2026-07-24 | RBC Capital | Target raised | Sector Perform | $490 → $580 |
Total return (dividends reinvested) (TMO)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +18.7% | +12.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +18.8% | +2.3% |
| Volatility (annualized) | 29.2% | 27.5% |
| Max drawdown | -31.4% (Jan 2026→May 2026) | -40.5% (Dec 2021→May 2025) |
TMO revenue by business segment (quarter ended Jun 27, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Laboratory Products and Biopharma Services | $6.69B | 55.8% | +11.6% |
| Life Sciences Solutions | $2.81B | 23.5% | +12.6% |
| Analytical Instruments | $1.85B | 15.4% | +6.9% |
| Specialty Diagnostics | $1.21B | 10.0% | +6.3% |
| Total revenue | $11.99B | 100% | — |
TMO revenue by product line (quarter ended Jun 27, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product revenues | $6.82B | 56.9% | +9.2% |
| — Consumables (part of Product revenues) | $5.07B | 42.3% | +10.1% |
| — Instruments (part of Product revenues) | $1.75B | 14.6% | +6.4% |
| Service revenues | $5.17B | 43.1% | +12.3% |
| Total revenue | $11.99B | 100% | — |
TMO revenue by region (quarter ended Jun 27, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| North America | $6.15B | 51.3% | +7.5% |
| Europe | $3.31B | 27.6% | +17.0% |
| Asia-Pacific | $2.10B | 17.5% | +9.6% |
| Other regions | $430.0M | 3.6% | +12.3% |
| Total revenue | $11.99B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
Companies that name TMO in their SEC reports
| Relationship to TMO | Company | Filing | Sentence |
|---|---|---|---|
| partner | BIO-TECHNE Corp (TECH) | 10-K Aug 24, 2026 | “We sell our products directly to customers who are primarily located in North America, Europe and China, as well as through a distribution agreement with Thermo Fisher Scientific.” |
| competitor | TRINITY BIOTECH PLC (TRIB) | 20-F Apr 30, 2026 | “The Group's competition includes several large companies such as, but not limited to: Abbott Diagnostics, Arkray, Becton Dickenson, Bio-Rad, Copan, Dexcom Inc., Diasorin Inc., Johnson & Johnson, Roche Diagnostics, Sebia, Siemens (from the combined acquisitions of Bayer, Dade-Behring and DPC), Thermo Fisher, Tosoh and Werfen.” |
| supplier | Banzai International, Inc. (PARA) | 10-K Mar 31, 2026 | “Our customers include Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, Fitch Group, and many other globally recognized brands.” |
| competitor | VOLITIONRX LTD (VNRX) | 10-K Mar 31, 2026 | “We face competition primarily from other human-focused healthcare, pharmaceutical and diagnostic companies such as Exact Sciences Corporation, Guardant Health, GRAIL Inc., Natera, Caris Life Sciences, Freenome Holdings Inc, CellMax Life, Archer DX Inc., Foundation Medicine Inc., Oncocyte Corporation, OpKo Health Inc., MDNA Life Sciences Inc., Abbott Laboratories Inc., Cepheid Inc., Hologic Corporation, Agilent Tec…” |
| partner | AIM ImmunoTech Inc. (AIM) | 10-K Mar 27, 2026 | “March 2026, we announced an agreement with the PPD clinical research business of Thermo Fisher Scientific to design AIM's” |
| customer | Humacyte, Inc. (HUMA) | 10-K Mar 27, 2026 | “We source bioprocess solutions, including culture media and decellularization buffers, from a division of Thermo Fisher Scientific, which has a second production site to provide redundant media/buffer production capacity.” |
| partner | CAPRICOR THERAPEUTICS, INC. (CAPR) | 10-K Mar 17, 2026 | “On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of certain cells which we are utilizing in connection with the development of our exosomes platform.” |
| partner | Theriva Biologics, Inc. (TOVX) | 10-K Mar 12, 2026 | “Our OV platform viruses (e.g. VCN-01, VCN-11, and VCN - 12) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, Recipharm Advanced Bio, Fujifilm Diosynth and others.” |
| competitor | 908 Devices Inc. (MASS) | 10-K Mar 9, 2026 | “We have a range of competitors extending from small, privately held companies with single-point solutions to large, publicly-held corporations, including those with a portfolio of Mass Spec and/or spectroscopy products, such as Agilent, Bruker, Danaher, Inficon, Teledyne, Rigaku, and Thermo Fisher Scientific.” |
| partner | Stevanato Group S.p.A. (STVN) | 20-F Mar 4, 2026 | “In 2023 we announced a strategic collaboration with Thermo Fisher Scientific who will provide fill-and-finish and final assembly services related to Vertiva®.” |
| competitor | Quantum-Si Inc (QSI) | 10-K Mar 3, 2026 | “We also may compete with a number of emerging growth companies that have developed, or are developing, proteomic products and solutions, such as Nautilus Biotechnology, Olink Proteomics (acquired by Thermo Fisher Scientific), Quanterix, Seer and SomaLogic (acquired by Illumina, Inc.).” |
| competitor | SOPHiA GENETICS SA (SOPH) | 20-F Mar 3, 2026 | “We also face competition from companies that have developed software analytics platforms for genomics data, such as Agilent, Fabric Genomics, Illumina, Qiagen Digital Insights, Velsera Inc., Congenica Ltd and Thermo Fisher.” |
| customer | Sarepta Therapeutics, Inc. (SRPT) | 10-K Mar 2, 2026 | “$120.2 million decrease in manufacturing expenses primarily due to costs associated with the termination of the development, commercial manufacturing and supply agreement (the "Thermo Agreement") related to Brammer Bio MA, LLC, an affiliate of Thermo Fisher Scientific, Inc. ("Thermo") in 2024, with no similar activity in 2025;” |
| competitor | Alpha Teknova, Inc. (TKNO) | 10-K Mar 2, 2026 | “Our Lab Essentials and Clinical Solutions products compete, based on turnaround time, performance, and quality, with products offered by numerous large, established life science companies such as Thermo Fisher, Millipore (Merck KGaA), Cytiva (Danaher), and Hardy Diagnostics, as well as smaller, companies such as GeminiBio, Boston BioProducts, and Biologos.” |
| competitor | Quanterix Corp (QTRX) | 10-K Mar 2, 2026 | “Our Accelerator Laboratory competes with other research laboratories such as LabCorp, Covance, Q2 Solutions, Rules Based Medicine, Monogram Biosciences, Frontage, Thermo Fisher Scientific, and others, some of which are customers of ours.” |
TMO company outlook (results filed Oct 21, 2026)
- “Guidance for 2026 The company will provide updated 2026 financial guidance during its earnings conference call this morning at 7:00 a.m.”
Quoted word-for-word from the SEC 8-K results press release.
TMO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $7.14 | $7.29 | -2.1% | $12.86B | 21 |
| Next quarter (ends Mar 2027) | $6.05 | $5.99 | +1.0% | $11.74B | 13 |
| Current fiscal year (ends Dec 2026) | $25.25 | $25.09 | +0.7% | $47.99B | 27 |
| Next fiscal year (ends Dec 2027) | $27.76 | $27.45 | +1.1% | $50.52B | 27 |
TMO options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 36.5% | ±4.3% |
| Nov 6, 2026 | 14 | 35.1% | ±5.7% |
| Nov 13, 2026 | 21 | 33.9% | ±6.7% |
| Nov 20, 2026 | 28 | 32.8% | ±7.4% |
| Nov 27, 2026 | 35 | 31.6% | ±8.0% |
| Dec 4, 2026 | 42 | 30.7% | ±8.5% |
| Dec 18, 2026 | 56 | 31.9% | ±10.1% |
| Jan 15, 2027 | 84 | 30.9% | ±11.9% |
30-day implied volatility 31.5% vs 28% realized over the last 30 trading days. Put/call ratio (volume) 0.6. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:14 UTC)
| Price | USD 676.54 |
|---|---|
| Change | ▼ 2.52% (down) |
| Previous Close | USD 694.02 |
| Open | USD 691.7 |
| Day Range | USD 674.2 – 703.2 |
| 52-Week Range | USD 435.27 – 705.79 |
| Volume | 3,599,891 shares |
| Market Cap | $250.15B |
| Exchange | NYQ |
Technical Analysis (TMO)
Nexqual's technical model rates TMO "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:14 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.24 (neutral) |
| vs SMA50 | Above (USD 643.4) |
| MACD | 12.38 (positive) |
Analyst Ratings (TMO)
Wall Street analysts rate TMO "Buy" based on 27 analysts, with a mean price target of USD 750.92 (range USD 560–830), per Nexqual as of October 23, 2026 at 09:14 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 750.92 |
| High Target | USD 830 |
| Low Target | USD 560 |
| Buy / Hold / Sell | 23 / 3 / 1 |
Earnings (TMO)
| Next Earnings Date | 2026-10-21 |
|---|---|
| EPS Estimate | USD 7.14 |
| Revenue Estimate | $12.86B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 6.68 vs est 6.4 ▲ beat |
| 2026-06-30 | USD 6.03 vs est 5.71 ▲ beat |
| 2026-03-31 | USD 5.44 vs est 5.24 ▲ beat |
| 2025-12-31 | USD 6.57 vs est 6.45 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:14 UTC.
Financials & Fundamentals (TMO)
| Total Revenue | $47.35B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +9.10% |
| Gross Margin | +41.13% |
| Operating Margin | +20.29% |
| Profit Margin | +14.94% |
| ROE | +13.38% |
| Debt / Equity | 0.75 |
| Current Ratio | 1.81 |
| Total Cash | $6.06B |
| Total Debt | $41.37B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $7.32B (15.8% of revenue) |
Source: Nexqual, October 23, 2026 at 09:14 UTC.
Financial Health Score (TMO)
Nexqual rates Thermo Fisher Scientific Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:14 UTC.
| Growth | Mixed — Revenue +3.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 41%, operating 20% (last 12 months) |
| Balance Sheet | Mixed — $4.06B cash and investments vs $45.7B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $7.32B (last 4 quarters to Jun 2026, SEC), 16% margin |
| Efficiency | Mixed — ROE 13%, ROA 5.2% |
Ownership (TMO)
| Insider Ownership | +0.13% |
|---|---|
| Institutional Ownership | +94.07% |
| Shares Outstanding | 369.75M |
| Float | 369.07M |
| Short % of Float | +1.46% |
Source: Nexqual, October 23, 2026 at 09:14 UTC.
Leadership (TMO)
Thermo Fisher Scientific Inc. is led by Marc N. Casper, Chairman & CEO, per Nexqual as of October 23, 2026 at 09:14 UTC.
| Chairman & CEO | Marc N. Casper |
|---|---|
| President, COO & President of Products and Technologies | Gianluca Pettiti |
| Senior VP & CFO | James R. Meyer |
| Chief Scientific Officer | Karen E. Nelson |
| Vice President of Investor Relations | Rafael Tejada |
Major Backers & Investors (TMO)
Notable institutional backers of Thermo Fisher Scientific Inc. include FMR, LLC, Morgan Stanley, Fidelity, according to Nexqual as of October 23, 2026 at 09:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 3.81% |
| Morgan Stanley | 2.91% |
| Fidelity | 2.42% |
| JPMorgan | 2.3% |
| Franklin Resources, Inc. | 1.97% |
| Capital Group | 1.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.36% |
| Vanguard Group | 8.25% |
| State Street | 4.55% |
| Geode Capital | 2.27% |
Source: Nexqual, October 23, 2026 at 09:14 UTC.
From Thermo Fisher Scientific Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
- Our global team delivers a combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
- Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more innovative, productive and cost-efficient.
- We have approximately 14,000 sales personnel including highly trained technical specialists who enable us to better meet the needs of our more technical end-users.
Legal & Regulatory Risks (Item 1A, quoted)
- New governmental regulations or changes in existing governmental regulations may reduce demand for our products or increase our expenses.
- We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenues associated with these customers.
- Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could suffer.
- We are subject to product and other liability risks for which we may not have adequate insurance coverage.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DHR | Danaher Corporation | USD 229.75 | ▼ 1.76% |
| NTRA | Natera, Inc. | USD 401.37 | ▼ 2.91% |
| A | Agilent Technologies, Inc. | USD 173.89 | ▼ 2.17% |
| IQV | IQVIA Holdings, Inc. | USD 278.32 | ▲ 0.61% |
| WAT | Waters Corporation | USD 455.59 | ▼ 0.41% |
| IDXX | IDEXX Laboratories, Inc. | USD 566.76 | ▲ 2.4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:14 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt